Table 1.
Baseline characteristics of patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD)
| Characteristic | Crohn’s disease, n=16 | Ulcerative colitis, n=18 |
|---|---|---|
| All Patients: n= 34 | ||
| Male gender, n (%) | 9 (56%) | 15 (83%) |
| Median age IBD diagnosis, years (IQR) | 19.5 (17–24) | 22 (18–39) |
| Median age, years (IQR) | 34 (25.5–38.5) | 37 (23–46) |
| Median duration of disease, years (IQR) | 10.5 (7.5–18.5)) | 10 (3–15) |
| Disease Location – Montreal Classification | L1 – 0 (0%) | 16 (100%) pan-colitis |
| L2 – 3 (19%) | ||
| L3 – 13 (81%) | ||
| P – 2 (13%) | ||
| Current smoker, n (%) | 2 (13%) | 0 (0%) |
| Clinical disease activity at baseline, n (%) | HBI | SCCAI: |
| <5 (remission): 5 (31%) | < 3 (remission): 4 (22%) | |
| 5–7 (mild): 5 (31%) | 3–6 (mild): 8 (44%) | |
| 8–16 (moderate): 6 (38%) | 7–10 (moderate): 4 (22%) | |
| > 16 (severe): 0 (0%) | > 10 (severe): 2 (11%) | |
| History of liver transplant, n (%) | 2 (13%) | 7 (39%) |
| Recurrent PSC in transplanted liver, n (%) | 1 (50%) | 2 (25%) |
| Active PSC at vedolizumab commencement, n (%) | 15 (94%) | 13 (72%) |
| Anti-TNF treatment naïve, n (%) | 1 (6%) | 6 (33%) |
| Concomitant medications at commencement, n (%) | ||
| Tacrolimus | 2 (13%) | 7 (39%) |
| Immunomodulator | 6 (38%) | 7 (39%) |
| Glucocorticoids | 4 (25%) | 8 (44%) |
| Antibiotics | 1 (6%) | 1 (6%) |
| Median prednisolone equivalent dose, mg (IQR) | 40 (30–40) | 15 (10–40) |
| Patients with PSC and biochemical testing before and after vedolizumab: n = 26 | ||
| Median age of PSC diagnosis, years (IQR) | 24 (20–29) | 22 (20–43) |
| Median duration of PSC, years (IQR) | 8 (3–10) | 3 (1–8) |
| Cirrhosis, n (%) | 2 (14%) | 0 (0%) |
| History of biliary stricture dilation, n (%) | 5 (36%) | 4 (33%) |
| On UDCA, n (%) | 5 (36%) | 2 (17%) |
| Median daily urosodeoxycholic acid dose, mg (IQR) | 900 (900–1000) | 1000 (1000–1000) |
| Biochemistry at baseline, median (IQR) | ||
| Alkaline phosphatase (IU/L) (normal < 120) | 268 (99–551) | 283 (108–618) |
| Aspartate aminotransferase (IU/L) (normal < 30) | 34 (24–98) | 81 (50–111) |
| Alanine aminotransferase (IU/L) (normal < 120) | 42 (20–144) | 86 (27–139) |
| Albumin (g/dL) (normal 3.9–4.4) | 3.5 (2.9–4.5) | 4.1 (3.9–4.3) |
| Total bilirubin (mg/dl) | 0.5 (0.4–0.6) | 0.8 (0.6–1.6) |
| Baseline Mayo Risk Score, mean (95%CI) | −0.55 (−1.38–0.27) | −0.26 (−0.81 – 0.29) |